<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827059</url>
  </required_header>
  <id_info>
    <org_study_id>NL 42568.018.12</org_study_id>
    <nct_id>NCT01827059</nct_id>
  </id_info>
  <brief_title>Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE</brief_title>
  <acronym>BICYCLE</acronym>
  <official_title>A Randomized Placebo Controlled Trial to Analyze Changes in Pulmonary Arterial Pressures at Peak Exercise in Congenital Heart Disease Patients With Exercise-induced Pulmonary Arterial Hypertension Before and After Treatment With Bosentan, Compared to Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SUMMARY Rationale: Pulmonary arterial hypertension (PAH) can be a rapidly progressive&#xD;
      disorder and is associated with a high mortality rate, despite medical intervention. With the&#xD;
      availability of effective therapy, early disease detection is an important strategic&#xD;
      objective to improve treatment outcomes. Resting echocardiography is currently the&#xD;
      recommended screening modality for high-risk population groups. However, it is clear that&#xD;
      abnormalities in resting hemodynamics (and symptoms) are late sequelae of the pathobiological&#xD;
      processes that begin in the distal pulmonary arteries. Exercise stress may unmask early&#xD;
      pulmonary vascular dysfunction, however the definition, clinical significance, and natural&#xD;
      history of 'exercise PAH' remain undefined. However, based on clinical experience and&#xD;
      literature the prevalence is estimated at ~ 20%.Treatment with endothelin receptor blockers&#xD;
      has shown a beneficial influence on the clinical performance in patients with exercise&#xD;
      induced PAH due to systemic sclerosis and primary pulmonary hypertension. Whether endothelin&#xD;
      receptor blockers decrease pulmonary pressures and improve clinical outcome in patients with&#xD;
      exercise induced pulmonary arterial hypertension due to congenital heart disease is unknown.&#xD;
&#xD;
      Objective: Identify congenital heart disease patients with exercise-induced pulmonary&#xD;
      arterial hypertension. Analyze changes in pulmonary arterial pressures at peak exercise in&#xD;
      patients with exercise induced pulmonary arterial hypertension before and after treatment&#xD;
      with bosentan, compared to placebo.&#xD;
&#xD;
      Study design: Randomized placebo controlled trial with a study period of 26 weeks.&#xD;
&#xD;
      Study population: Adult congenital heart disease patients with exercise induced pulmonary&#xD;
      arterial hypertension (n=40) from the Academic Medical Centre, Amsterdam.&#xD;
&#xD;
      Intervention: After randomization one group (n=20) receives a 125 mg tablet of Bosentan twice&#xD;
      daily for 6 months. The other group (n=20) receives placebo for 6 months.&#xD;
&#xD;
      Main study parameters/endpoints: To determine wether bosentan (endothelin receptor inhibitor)&#xD;
      decreases mean pulmonary arterial pressure at peak exercise in adult congenital heart disease&#xD;
      patients with exercise induced pulmonary arterial hypertension. Furthermore the change in&#xD;
      cardiopulmonary exercise capacity and right ventricular function will be investigated.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: All investigations, blood analysis excepted, are non-invasive and free of risk.&#xD;
      The burden for the patients mainly consists of the time that is consumed by the&#xD;
      investigations, namely: history taking + physical examination (15 min); Quality-of-Life-&#xD;
      score (15 min); laboratory tests (electrolytes, creatinine, urea, albumin and neurohormones,&#xD;
      troponin T); 12 lead electrocardiogram (10 min); exercise echocardiography (30 min);&#xD;
      cardiovascular exercise testing (30 min).&#xD;
&#xD;
      The trial medication has a potential risk of liver damage, which will be monitored regularly&#xD;
      by laboratory testing of liver transaminases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean pulmonary arterial pressure (mPAP) at peak exercise</measure>
    <time_frame>26 weeks</time_frame>
    <description>measured by means of transthoracic echocardiography at 3 and 6 months followup: mPAP = 0.6 x systolic PAP.&#xD;
peak exercise is defined as 80% of maximum calculated heart rate: peak exercise=0.8*(220-age)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary exercise capacity</measure>
    <time_frame>26 weeks</time_frame>
    <description>o i.e. peak oxygen consumption, VE/VCO2 ratio, O2 pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary hemodynamics</measure>
    <time_frame>26 weeks</time_frame>
    <description>o i.e. systolic pulmonary arterial pressure, pulmonary vascular resistance, pressure-flow relationships during and at peak exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular function</measure>
    <time_frame>26 weeks</time_frame>
    <description>o i.e. TAPSE, TEI index, TDI-S, right ventricular dimensions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters</measure>
    <time_frame>26 weeks</time_frame>
    <description>o i.e. NT-pro BNP, troponin T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>26 weeks</time_frame>
    <description>o assessed by TAAQOL-CHD, SF-36 and Minnesota CHD-HF questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demographics</measure>
    <time_frame>26 weeks</time_frame>
    <description>age, gender, marital status, work, income.&#xD;
assessed by demographic questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tracleer, 125-mg orange-white, round, biconvex, film-coated tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>125-mg orange-white, round, biconvex, film-coated tablets</description>
    <arm_group_label>Bosentan</arm_group_label>
    <other_name>Tracleer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult (&gt;18 years) and mentally competent&#xD;
&#xD;
          -  Open or closed septal defect (ASD I/II, VSD, AVSD)&#xD;
&#xD;
          -  Open or closed systemic-to-pulmonary shunt (PDA, PAPVC)&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Presence of X-PAH&#xD;
&#xD;
               -  One of the following criteria, at peak exercise.&#xD;
&#xD;
               -  mPAP &gt; 34 mmHg with CO ≤ 10 l/min&#xD;
&#xD;
               -  mPAP &gt; 40 mmHg with CO ≤ 15 l/min&#xD;
&#xD;
               -  mPAP &gt; 45 mmHg with CO ≤ 20 l/min&#xD;
&#xD;
               -  mPAP &gt; 50 mmHg with CO ≤ 30 l/min&#xD;
&#xD;
               -  a PVR (slope pressure/flow plot) of &gt; 3 mmHg/l/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incapable of giving informed consent&#xD;
&#xD;
          -  Pregnancy or lactation (a pregnancy test is offered to every female patient within&#xD;
             fertile age)&#xD;
&#xD;
          -  Women of child-bearing age who are sexually active without practising reliable methods&#xD;
             of contraception. The use of oral contraceptives only, is not considered reliable.&#xD;
             Reliable methods include concomitant use of oral contraceptives and condoms (&quot;Double&#xD;
             Dutch&quot;), and those methods with a less than 1% chance of pregnancy during typical&#xD;
             use20, including intrauterine contraceptives (Copper T, Mirena), Implanon, and&#xD;
             sterilization.&#xD;
&#xD;
          -  Substance abuse (alcohol, medicines, drugs)&#xD;
&#xD;
          -  Subjects who are not able to perform cardiopulmonary exercise testing&#xD;
&#xD;
          -  Any cardiac operation &lt; 6 months before inclusion&#xD;
&#xD;
          -  PAH of any aetiology other than the one specified in the inclusion criteria&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 30%&#xD;
&#xD;
          -  Significant impairment of renal function (GFR &lt; 30 ml/min/1.73m2)&#xD;
&#xD;
          -  Moderate to severe liver disease: Child Pugh class B or C&#xD;
&#xD;
          -  Raised plasma transaminases level &gt; three times upper normal limit&#xD;
&#xD;
          -  Arterial hypotension (systolic blood pressure &lt; 85mmHg)&#xD;
&#xD;
          -  Anaemia (Hb &lt; 10g/L, or &lt;6.21 mmol/L)&#xD;
&#xD;
          -  Significant valvular disease, other than tricuspid or pulmonary regurgitation&#xD;
&#xD;
          -  Chronic lung disease or total lung capacity &lt; 80% predicted value&#xD;
&#xD;
          -  History of significant pulmonary embolism&#xD;
&#xD;
          -  Other relevant diseases (HIV infection, Hep B/C infection)&#xD;
&#xD;
          -  Subjects with known intolerance to bosentan or their constituents&#xD;
&#xD;
          -  Prohibited medication: any medication listed below which has not been discontinued at&#xD;
             least 30 days prior to inclusion&#xD;
&#xD;
               -  Unspecified or other significant medication (glibenclamide or immunosuppression)&#xD;
&#xD;
               -  PAH therapy (endothelin receptor antagonists, PDE-5 inhibitors, prostanoids)&#xD;
&#xD;
               -  Medication which is not compatible with bosentan or interferes with its&#xD;
                  metabolism (inhibitors or inducers of CYP2C9, CYP3A4) or medication which may&#xD;
                  interfere with bosentan treatment according to the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.C.J.M. van Riel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>B.J. Bouma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>B.J.M. Mulder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Berto J Bouma</investigator_full_name>
    <investigator_title>Dr. B.J. Bouma, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

